Göteborgs Universitet Sahlgrenska Center for Cancer Research
- Address
- lock Available on a paid plan
Neoadjuvant Hormone Therapy in Postmenopausal Breast Cancer
The Göteborgs Universitet Sahlgrenska Center for Cancer Research is conducting research on ER‑positive/HER2‑negative breast cancer in the neoadjuvant setting, aiming to assess how adding the investigational agent PF‑07220060 to standard letrozole influences tumor proliferation.
- Evaluation of Ki‑67 as an early marker of treatment response
- Comparison of combination therapy versus letrozole alone
- Insights into hormone‑driven tumor biology
Findings may guide future treatment strategies for postmenopausal patients with hormone‑responsive disease.
Window‑of‑Opportunity Study in Premenopausal Breast Cancer
A separate trial at the same site explores short‑term hormone blockade in premenopausal women with ER‑positive/HER2‑negative early breast cancer, testing the novel oral selective estrogen receptor degrader giredestrant with and without the GnRH agonist triptorelin.
- Assessment of anti‑proliferative activity versus standard anastrozole
- Investigation of the added benefit of triptorelin to giredestrant
- Potential for non‑invasive biomarkers to predict response
Results could expand therapeutic options for younger patients undergoing surgery.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Göteborgs Universitet Sahlgrenska Center for Cancer Research
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Evaluation of Giredestrant and Triptorelin Versus Anastrozole and Triptorelin in Premenopausal ER-Positive/HER2-Negative Early Breast Cancer | ETOP IBCSG Partners Foundation | Phase II | Not Recruiting | Jan 2024 | Sep 2025 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 1 | Unknown | 2024-01-29 | 2024-01-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.